Endeavor reports mid-stage success for IPF drug with reversal potential
Endeavor BioMedicines said its idiopathic pulmonary fibrosis treatment met the main goal of a mid-stage trial. The company claims the drug may be able to reverse the disease’s progression.
Endeavor BioMedicines said a mid-stage study of its therapy for idiopathic pulmonary fibrosis achieved its main objective. The company also indicated the drug might be capable of reversing the disease’s progression. No further specifics about the trial or the drug were included in the available material. The announcement places the company’s candidate in the broader effort to develop new IPF therapies, but the reversal claim remains a company assertion that would need confirmation in later-stage research.
If the mid-stage result holds up, people living with idiopathic pulmonary fibrosis and their caregivers could see a new treatment option with the potential to reverse progression. Clinicians may gain another candidate to discuss, while payers and health systems could face questions about access and cost. Still, mid-stage success does not guarantee approval or real-world